Target Validation Information
TTD ID T22274
Target Name Histone deacetylase 6 (HDAC6)
Type of Target
Clinical trial
Drug Potency against Target (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Drug Info IC50 = 990 nM [3]
(S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide Drug Info IC50 = 3860 nM [14]
2-(methylsulfonylthio)ethyl 2-propylpentanoate Drug Info IC50 = 9600 nM [15]
4-Benzoylamino-N-hydroxy-benzamide Drug Info IC50 = 210 nM [11]
4-Butyrylamino-N-hydroxy-benzamide Drug Info IC50 = 1500 nM [6]
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Drug Info IC50 = 369 nM [4]
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Drug Info IC50 = 610 nM [9]
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Drug Info IC50 = 149 nM [1]
4-Phenylbutyrohydroxamic acid Drug Info Ki = 150 nM [20]
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Drug Info IC50 = 2580 nM [7]
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Drug Info IC50 = 450 nM [15]
5-Mercapto-pentanoic acid phenylamide Drug Info IC50 = 6200 nM [9]
6-(9H-carbazol-9-yl)-N-hydroxyhexanamide Drug Info IC50 = 41 nM [21]
6-benzenesulfinylhexanoic acid hydroxamide Drug Info IC50 = 60 nM [12]
6-benzenesulfonylhexanoic acid hydroxamide Drug Info IC50 = 40 nM [12]
6-Mercapto-hexanoic acid phenylamide Drug Info IC50 = 370 nM [9]
6-Phenoxy-hexane-1-thiol Drug Info IC50 = 11000 nM [9]
6-phenylsulfanylhexanoic acid hydroxamide Drug Info IC50 = 120 nM [12]
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Drug Info IC50 = 620 nM [3]
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Drug Info IC50 = 2600 nM [4]
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Drug Info IC50 = 1100 nM [3]
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Drug Info IC50 = 520 nM [3]
7-Mercapto-heptanoic acid benzothiazol-2-ylamide Drug Info IC50 = 340 nM [9]
7-Mercapto-heptanoic acid biphenyl-3-ylamide Drug Info IC50 = 75 nM [9]
7-Mercapto-heptanoic acid biphenyl-4-ylamide Drug Info IC50 = 1100 nM [9]
7-Mercapto-heptanoic acid pyridin-3-ylamide Drug Info IC50 = 110 nM [9]
7-Mercapto-heptanoic acid quinolin-3-ylamide Drug Info IC50 = 72 nM [9]
7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Drug Info IC50 = 41 nM [14]
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Drug Info IC50 = 2900 nM [3]
8-Mercapto-octanoic acid phenylamide Drug Info IC50 = 1500 nM [9]
8-Oxo-8-phenyl-octanoic acid Drug Info IC50 = 270 nM [1]
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Drug Info IC50 = 6700 nM [4]
Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Drug Info IC50 = 8.8 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Drug Info IC50 = 43 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Drug Info IC50 = 29 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Drug Info IC50 = 36 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Drug Info IC50 = 43 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Drug Info IC50 = 40 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Drug Info IC50 = 86 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Drug Info IC50 = 24 nM [13]
Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Drug Info IC50 = 26 nM [13]
Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Drug Info IC50 = 71 nM [13]
Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Drug Info IC50 = 12 nM [13]
Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Drug Info IC50 = 56 nM [13]
Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Drug Info IC50 = 33 nM [13]
Cyclostellettamine derivative Drug Info IC50 = 17000 nM [8]
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Drug Info IC50 = 2800 nM [10]
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Drug Info IC50 = 12500 nM [10]
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Drug Info IC50 = 1566 nM [4]
N-(6-Hydroxycarbamoyl-hexyl)-benzamide Drug Info IC50 = 568 nM [1]
N-(6-Mercapto-hexyl)-benzamide Drug Info IC50 = 360 nM [9]
N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide Drug Info IC50 = 1100 nM [16]
N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide Drug Info IC50 = 710 nM [16]
N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide Drug Info IC50 = 490 nM [16]
N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide Drug Info IC50 = 390 nM [16]
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Drug Info IC50 = 68 nM [11]
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Drug Info IC50 = 34 nM [11]
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Drug Info IC50 = 54 nM [11]
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Drug Info IC50 = 110 nM [11]
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Drug Info IC50 = 44 nM [11]
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Drug Info IC50 = 250 nM [11]
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Drug Info IC50 = 3600 nM [6]
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Drug Info IC50 = 2500 nM [6]
N-Hydroxy-4-phenylacetylamino-benzamide Drug Info IC50 = 157 nM [11]
N-phenyl-6-(sulfamoylamino)hexanamide Drug Info IC50 = 1500 nM [16]
N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide Drug Info IC50 = 4300 nM [5]
N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide Drug Info IC50 = 9 nM [16]
N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Drug Info IC50 = 5 nM [19]
N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide Drug Info IC50 = 3 nM [19]
NILTUBACIN Drug Info Ki = 2200 nM [20]
Octanedioic acid bis-hydroxyamide Drug Info IC50 = 1150 nM [2]
Octanedioic acid hydroxyamide pyridin-2-ylamide Drug Info IC50 = 248 nM [1]
Octanedioic acid hydroxyamide pyridin-4-ylamide Drug Info IC50 = 306 nM [1]
PSAMMAPLIN A Drug Info IC50 = 4 nM [4]
ST-2741 Drug Info IC50 = 6000 nM [18]
ST-2986 Drug Info IC50 = 661 nM [17]
ST-2987 Drug Info IC50 = 124 nM [17]
ST-3050 Drug Info IC50 = 303 nM [17]
References
REF 1 Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
REF 2 Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
REF 3 Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
REF 4 Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
REF 5 Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett. 2004 Jan 19;14(2):449-53.
REF 6 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
REF 7 Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
REF 8 Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
REF 9 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
REF 10 Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
REF 11 Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
REF 12 Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
REF 13 Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
REF 14 Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
REF 15 New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
REF 16 Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
REF 17 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
REF 18 Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3.
REF 19 Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
REF 20 Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
REF 21 Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.